Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs glucocorticoids in good-prognosis microscopic polyangiitis
2018-000637-12Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab in microscopic polyangiitis (MPA) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Disease-free survival from month 3 to month 18. Started Jan 2019; status: completed.
02
Drugs
rituximab
03
Conditions
microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on 2018-000637-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000637-12.